Patents Assigned to AMGEN K-A, INC.
  • IL-17 receptor A antigen binding proteins
    Patent number: 11858999
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: January 2, 2024
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Method of treating diseases using an IL-17 receptor antibody formulation
    Patent number: 11505612
    Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: November 22, 2022
    Assignee: AMGEN K-A, INC.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
  • IL-17 Receptor A antigen binding proteins
    Patent number: 11180564
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 23, 2021
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • IL-17 receptor antibody formulation
    Patent number: 10808033
    Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 20, 2020
    Assignee: Amgen K-A, Inc.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
  • IL-17 receptor A antigen binding proteins
    Patent number: 10208122
    Abstract: Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 19, 2019
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim